|Bid||0.8900 x 0|
|Ask||0.9400 x 0|
|Day's Range||0.8900 - 0.9400|
|52 Week Range||0.2500 - 2.0100|
|Beta (5Y Monthly)||0.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.25|
RICHMOND HILL, ON / ACCESSWIRE / January 13, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its ordinary shares.
RICHMOND HILL, ON / ACCESSWIRE / December 30, 2020 / Helix BioPharma Corp.
By John Vandermosten, CFA TSX:HBP.TO | OTC:HBPCF READ THE FULL HBP.TO RESEARCH REPORT First Quarter Fiscal Year 2021 Operational and Financial Results Helix BioPharma Corp. (TSX: HBP.TO) (OTC:HBPCF) reported first quarter fiscal year 2021 financial and operational results and submitted SEDAR filings on December 15, 2020. During 1Q:21, extending from August 1 to October 31, 2020,